Document is current
Any future updates will be listed below
-
Authors
Rekkas, Alexandros http://orcid.org/0000-0002-5352-943X
van Klaveren, David
Ryan, Patrick B.
Steyerberg, Ewout W. http://orcid.org/0000-0002-7787-0122
Kent, David M. http://orcid.org/0000-0002-9205-5070
Rijnbeek, Peter R.
-
Funding
Funding for this research was provided by:
Innovative Medicines Initiative (80696, 80696)
- License Information
-
More Information
Article History
Received: 1 July 2022
Accepted: 10 March 2023
First Online: 30 March 2023
Competing interests
: A.R. and P.R.R. work for a group that received unconditional research grants from Boehringer-Ingelheim, GSK, Janssen Research & Development, Novartis, Pfizer, Yamanouchi, and Servier. None of these grants result in a conflict of interest for the content of this paper. P.B.R. is an employee of Janssen R&D, subsidiary of Johnson & Johnson. D.V.K., D.M.K., E.W.S. have nothing to declare.
